Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.35 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.35 |
| ▸ | PGR | P06401 | 1/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | AKT1 | P31749 | 2/20 | 0.34 |
| ▸ | CES2 | O00748 | 1/20 | 0.34 |
| ▸ | CES1 | P23141 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | PPARA | Q07869 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17896140 | 1.00 | AAK1 (0.43) | AAK1ALDH1A1TSHRGRIK1GRIK2 | |
| SCHEMBL17902787 | 0.82 | AAK1 (0.64) | AAK1ALDH1A1TSHRPPARGPPARA | |
| SCHEMBL5779986 | 0.81 | CYP2C19 (0.49) | AAK1ALDH1A1TSHRAKT1CES1 | |
| SCHEMBL5779979 | 0.81 | CYP2C19 (0.49) | AAK1ALDH1A1TSHRAKT1CES1 | |
| SCHEMBL5779984 | 0.81 | CYP2C19 (0.49) | AAK1ALDH1A1TSHRAKT1CES1 | |
| SCHEMBL381892 | 0.78 | AAK1 (0.48) | AAK1ALDH1A1TSHRPGRADRA2A | |
| SCHEMBL16119517 | 0.76 | AAK1 (0.47) | AAK1ALDH1A1TSHRPGRADRA2A | |
| SCHEMBL14879812 | 0.76 | AAK1 (0.47) | AAK1ALDH1A1TSHRPGRADRA2A | |
| SCHEMBL14879975 | 0.76 | TSHR (0.53) | AAK1ALDH1A1TSHRHDAC3LMNA | |
| SCHEMBL16119509 | 0.76 | TSHR (0.53) | AAK1ALDH1A1TSHRHDAC3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3240777-B1 | ARGINASE INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | ONCOARENDI THERAPEUTICS SA (PL) | 2019-07-24 | — | — | EP | disclosed |
| US-10329310-B2 | Arginase inhibitors and their therapeutic applications | ONCO ARENDI THERAPEUTICS S.A. (PL) | 2019-06-25 | — | — | US | disclosed |
| US-20180009830-A1 | ARGINASE INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | ONCO ARENDI THERAPEUTICS S.A. (PL) | 2018-01-11 | — | — | US | disclosed |
| EP-3240777-A1 | ARGINASE INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | ONCOARENDI THERAPEUTICS S.A. (PL) | 2017-11-08 | — | — | EP | disclosed |
| WO-2016108707-A1 | ARGINASE INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | OncoArendi Therapeutics Sp. z o.o. (PL) | 2016-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180009830-A1 | ARGINASE INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | ARG1, ARG2, PRMT1 | AAK1 1908/4885ALDH1A1 607/4885TSHR 1897/4885 |
| US-10329310-B2 | Arginase inhibitors and their therapeutic applications | ARG1, ARG2, PRMT1 | AAK1 1908/4885ALDH1A1 607/4885TSHR 1897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.